Levosimendan Eql Pharma

Levosimendan, the active ingredient in Levosimendan Eql Pharma, is a calcium sensitizer presented as an injectable solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in adult patients. GNH USA supplies Levosimendan Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan acts on the cardiovascular system to improve cardiac performance in severe heart failure conditions.

Acute decompensated heart failure: enhances cardiac output and relieves symptoms of congestion. Cardiogenic shock: provides hemodynamic support and stabilises blood pressure. Severe left ventricular dysfunction: offers inotropic support without raising intracellular calcium levels.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate. - Dizziness: feeling light‑headed.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: marked drop in blood pressure requiring intervention. - Anaphylactic reactions: rare allergic response. - Elevated liver enzymes: indication of hepatic stress.

Levosimendan requires careful monitoring and specific precautions before and during therapy. - Renal impairment: assess renal function and adjust infusion as needed. - Hepatic impairment: use with caution in patients with severe liver disease. - Hypotension: avoid rapid bolus; monitor blood pressure continuously. - Concomitant vasodilators: may potentiate hypotensive effect. - Pregnancy: safety unknown; avoid unless essential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Other inotropes (e.g., dobutamine): increase risk of arrhythmias. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt hemodynamic response. - Diuretics: can affect electrolyte balance. - Anticoagulants: hypotension may enhance bleeding tendency.